Vapotherm Reports Fourth Quarter and Fiscal Year 2022 Financial Results
Vapotherm, Inc. (NYSE: VAPO) reported a total revenue of $18.7 million for Q4 2022, reflecting a 16.1% decline from the previous year. For the fiscal year, revenue was $66.8 million, a 41% drop. The decrease is attributed to reduced demand for products linked to COVID-related hospitalizations. The company successfully completed its manufacturing transition to Mexico and launched the HVT 2.0 platform. Net loss for Q4 was $21.4 million, or $0.78 per share, while the total net loss for the year reached $113.3 million, or $4.24 per share. Looking ahead, VAPO anticipates revenue between $77 million and $79 million for 2023.
- Successful launch of the next generation HVT 2.0 platform.
- Streamlined cost structure resulting in a reduction of non-GAAP cash operating expenses from $100.8 million in 2021 to $83.6 million in 2022.
- Completion of a $23 million equity raise, strengthening the balance sheet.
- Total revenue decreased by 41% year-over-year.
- Net loss for FY 2022 increased to $113.3 million from $59.8 million in 2021.
- Gross margin fell to 25.8% in 2022 from 46.9% in 2021.
Fourth Quarter 2022 Summary
-
Total revenue for the fourth quarter of 2022 was
$18.7 million -
Gross margin was
27.5% in the fourth quarter of 2022 -
Substantially completed move of manufacturing operations from
New Hampshire toMexico
Fiscal Year 2022 Summary
-
Total revenue for 2022 was
$66.8 million - Launched next generation High Velocity Therapy platform, HVT 2.0
-
Cost structure has been streamlined which resulted in a decrease in non-GAAP cash operating expenses from
in 2021 to$100.8 million in 2022$83.6 million - Worldwide installed base of High Velocity Therapy systems grew by approximately 1,600 units in 2022, now at over 36,700 units
“2022 was a year of transition as we repositioned the business given the significant decrease in COVID-related hospitalizations as compared to 2020 and 2021,” said Joseph Army, President and CEO. “We executed on our path to profitability initiatives while still making investments in future growth drivers including the launch of our next generation platform, HVT 2.0. Recently, we completed a
Results for the Three Months
The following table reflects the Company’s net revenue for the three months ended
|
|
Three Months Ended |
|
|
|
|
|
|
|
|||||||||||||||
|
|
2022 |
|
|
2021 |
|
|
Change |
|
|||||||||||||||
|
|
(in thousands, except percentages) |
|
|||||||||||||||||||||
|
|
Amount |
|
|
% of Revenue |
|
|
Amount |
|
|
% of Revenue |
|
|
$ |
|
|
% |
|
||||||
Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Capital (product & lease revenue) |
|
$ |
3,039 |
|
|
|
16.3 |
% |
|
$ |
5,357 |
|
|
|
24.1 |
% |
|
$ |
(2,318 |
) |
|
|
(43.3 |
)% |
Disposables |
|
|
14,113 |
|
|
|
75.6 |
% |
|
|
15,007 |
|
|
|
67.5 |
% |
|
|
(894 |
) |
|
|
(6.0 |
)% |
Service and other |
|
|
1,511 |
|
|
|
8.1 |
% |
|
|
1,880 |
|
|
|
8.4 |
% |
|
|
(369 |
) |
|
|
(19.6 |
)% |
Total net revenue |
|
$ |
18,663 |
|
|
|
100.0 |
% |
|
$ |
22,244 |
|
|
|
100.0 |
% |
|
$ |
(3,581 |
) |
|
|
(16.1 |
)% |
Net revenue for the fourth quarter of 2022 was
Revenue information by geography is summarized as follows:
|
|
Three Months Ended |
|
|
|
|
|
|
|
|||||||||||||||
|
|
2022 |
|
|
2021 |
|
|
Change |
|
|||||||||||||||
|
|
(in thousands, except percentages) |
|
|||||||||||||||||||||
|
|
Amount |
|
|
% of Revenue |
|
|
Amount |
|
|
% of Revenue |
|
|
$ |
|
|
% |
|
||||||
|
|
$ |
15,531 |
|
|
|
83.2 |
% |
|
$ |
17,798 |
|
|
|
80.0 |
% |
|
$ |
(2,267 |
) |
|
|
(12.7 |
)% |
International |
|
|
3,132 |
|
|
|
16.8 |
% |
|
|
4,446 |
|
|
|
20.0 |
% |
|
|
(1,314 |
) |
|
|
(29.6 |
)% |
Total net revenue |
|
$ |
18,663 |
|
|
|
100.0 |
% |
|
$ |
22,244 |
|
|
|
100.0 |
% |
|
$ |
(3,581 |
) |
|
|
(16.1 |
)% |
Gross profit and gross margin for the fourth quarter of 2022 was
Total operating expenses were
Net loss for the fourth quarter of 2022 was
Adjusted EBITDA was negative
Results for the Year Ended
The following table reflects the Company’s net revenue for the years ended
|
|
Year Ended |
|
|
|
|
|
|
|
|||||||||||||||
|
|
2022 |
|
|
2021 |
|
|
Change |
|
|||||||||||||||
|
|
(in thousands, except percentages) |
|
|||||||||||||||||||||
|
|
Amount |
|
|
% of Revenue |
|
|
Amount |
|
|
% of Revenue |
|
|
$ |
|
|
% |
|
||||||
Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Capital Equipment (product & lease revenue) |
|
$ |
11,650 |
|
|
|
17.4 |
% |
|
$ |
40,096 |
|
|
|
35.4 |
% |
|
$ |
(28,446 |
) |
|
|
(70.9 |
)% |
Disposable |
|
|
46,368 |
|
|
|
69.4 |
% |
|
|
66,631 |
|
|
|
58.8 |
% |
|
|
(20,263 |
) |
|
|
(30.4 |
)% |
Service and Other |
|
|
8,783 |
|
|
|
13.2 |
% |
|
|
6,565 |
|
|
|
5.8 |
% |
|
|
2,218 |
|
|
|
33.8 |
% |
Net revenue |
|
$ |
66,801 |
|
|
|
100.0 |
% |
|
$ |
113,292 |
|
|
|
100.0 |
% |
|
$ |
(46,491 |
) |
|
|
(41.0 |
)% |
Net revenue for 2022 was
Revenue information by geography is summarized as follows:
|
|
Year Ended |
|
|
|
|
|
|
|
|||||||||||||||
|
|
2022 |
|
|
2021 |
|
|
Change |
|
|||||||||||||||
|
|
(in thousands, except percentages) |
|
|||||||||||||||||||||
|
|
Amount |
|
|
% of Revenue |
|
|
Amount |
|
|
% of Revenue |
|
|
$ |
|
|
% |
|
||||||
|
|
$ |
52,591 |
|
|
|
78.7 |
% |
|
$ |
84,147 |
|
|
|
74.3 |
% |
|
$ |
(31,556 |
) |
|
|
(37.5 |
)% |
International |
|
|
14,210 |
|
|
|
21.3 |
% |
|
|
29,145 |
|
|
|
25.7 |
% |
|
|
(14,935 |
) |
|
|
(51.2 |
)% |
Net Revenue |
|
$ |
66,801 |
|
|
|
100.0 |
% |
|
$ |
113,292 |
|
|
|
100.0 |
% |
|
$ |
(46,491 |
) |
|
|
(41.0 |
)% |
Gross profit for the year ended
Operating expenses were
Net loss for the year ended
Adjusted EBITDA was negative
Cash Position
Cash and cash equivalents were
Fiscal 2023 Outlook
For fiscal 2023, the Company expects net revenue to be in the range of
For fiscal 2023, gross margin is expected to be in the range of
For fiscal 2023, operating expenses are expected to be in the range of
For fiscal 2023, non-GAAP cash operating expenses excluding additional items as detailed below are expected to be in the range of
Conference Call Information
Management will host a conference call at
Website Information
Non-GAAP Financial Measures
This press release includes non-GAAP financial measures, including EBITDA, Adjusted EBITDA, non-GAAP operating expenses excluding impairment of long-lived assets, impairment of goodwill and loss on disposal of property and equipment, and non-GAAP cash operating expenses excluding additional items, including stock-based compensation expense, depreciation and amortization, severance accruals recorded, loss from deconsolidation, and change in fair value of contingent consideration, which differ from operating expenses calculated in accordance with
These non-GAAP financial measures are presented because the Company believes they are useful indicators of its operating performance. Management uses these non-GAAP financial measures, as measures of the Company’s operating performance and for planning purposes, including the preparation of the Company’s annual operating budget and financial projections. The Company believes these measures are useful to investors as supplemental information because they are frequently used by analysts, investors and other interested parties to evaluate companies in its industry. The Company believes Adjusted EBITDA is useful to its management and investors as a measure of comparative operating performance from period to period.
These non-GAAP financial measures should not be considered alternatives to, or superior to, net income or loss as a measure of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP. They should not be construed to imply that the Company’s future results will be unaffected by unusual or non-recurring items. In addition, Adjusted EBITDA is not intended to be a measure of free cash flow for management’s discretionary use, as it does not reflect certain cash requirements such as tax payments, debt service requirements, capital expenditures and certain other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our capital expenditures, cash requirements for working capital needs and cash costs to replace assets being depreciated and amortized. In evaluating Adjusted EBITDA, you should be aware that in the future the Company may incur expenses that are the same as or similar to some of the adjustments in this presentation. The Company’s presentation of Adjusted EBITDA should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company’s GAAP results in addition to using Adjusted EBITDA and other non-GAAP financial measures on a supplemental basis. The Company’s definitions of Adjusted EBITDA and non-GAAP operating expenses excluding impairment of long-lived assets, impairment of goodwill and loss on disposal of property and equipment and non-GAAP cash operating expenses excluding the additional items detailed below, are not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation.
About
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995, including statements about the Company’s expected net revenue, gross margin, operating expenses and non-GAAP cash operating expenses for fiscal year 2023 and its expectations to execute on its path-to-profitability initiative, which the Company believes will allow it to achieve its goals in 2023 and beyond. In some cases, you can identify forward-looking statements by terms such as “expect,” “continue,” “plan,” “intend,” “will,” “outlook,” “guidance,” or “typically,” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words, and the use of future dates. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include, but are not limited to the following:
Financial Statements:
|
||||||||
CONSOLIDATED BALANCE SHEETS |
||||||||
(In thousands, except share amounts) |
||||||||
|
|
|
|
|||||
|
|
2022 |
|
|
2021 |
|
||
Assets |
|
|
|
|
|
|
||
Current assets |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
15,738 |
|
|
$ |
57,071 |
|
Accounts receivable, net |
|
|
9,102 |
|
|
|
10,909 |
|
Inventories |
|
|
32,980 |
|
|
|
36,562 |
|
Prepaid expenses and other current assets |
|
|
2,081 |
|
|
|
5,205 |
|
Total current assets |
|
|
59,901 |
|
|
|
109,747 |
|
Property and equipment, net |
|
|
26,636 |
|
|
|
22,157 |
|
Operating lease right-of-use assets |
|
|
5,805 |
|
|
|
7,045 |
|
Restricted cash |
|
|
1,109 |
|
|
|
253 |
|
|
|
|
536 |
|
|
|
15,300 |
|
Intangible assets, net |
|
|
- |
|
|
|
4,398 |
|
Deferred income tax assets |
|
|
96 |
|
|
|
78 |
|
Other long-term assets |
|
|
2,112 |
|
|
|
1,107 |
|
Total assets |
|
$ |
96,195 |
|
|
$ |
160,085 |
|
Liabilities and Stockholders’ (Deficit) Equity |
|
|
|
|
|
|
||
Current liabilities |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
2,739 |
|
|
$ |
5,923 |
|
Contract liabilities |
|
|
1,216 |
|
|
|
2,081 |
|
Accrued expenses and other current liabilities |
|
|
15,609 |
|
|
|
28,559 |
|
Revolving loan facility |
|
|
- |
|
|
|
6,608 |
|
Total current liabilities |
|
|
19,564 |
|
|
|
43,171 |
|
Long-term loans payable, net |
|
|
96,994 |
|
|
|
39,726 |
|
Other long-term liabilities |
|
|
7,827 |
|
|
|
10,521 |
|
Total liabilities |
|
|
124,385 |
|
|
|
93,418 |
|
Commitments and contingencies |
|
|
|
|
|
|
||
Stockholders’ (deficit) equity |
|
|
|
|
|
|
||
Preferred stock ( |
|
|
- |
|
|
|
- |
|
Common stock ( |
|
|
29 |
|
|
|
26 |
|
Additional paid-in capital |
|
|
461,940 |
|
|
|
443,358 |
|
Accumulated other comprehensive (loss) income |
|
|
(157 |
) |
|
|
26 |
|
Accumulated deficit |
|
|
(490,002 |
) |
|
|
(376,743 |
) |
Total stockholders’ (deficit) equity |
|
|
(28,190 |
) |
|
|
66,667 |
|
Total liabilities and stockholders’ (deficit) equity |
|
$ |
96,195 |
|
|
$ |
160,085 |
|
|
||||||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS |
||||||||||||||||
(In thousands, except share and per share amounts) |
||||||||||||||||
|
|
Three Months Ended
|
|
|
Year Ended
|
|
||||||||||
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
||||
|
|
(unaudited) |
|
|
|
|
||||||||||
Net revenue |
|
$ |
18,663 |
|
|
$ |
22,244 |
|
|
$ |
66,801 |
|
|
$ |
113,292 |
|
Cost of revenue |
|
|
13,540 |
|
|
|
14,455 |
|
|
|
49,558 |
|
|
|
60,104 |
|
Gross profit |
|
|
5,123 |
|
|
|
7,789 |
|
|
|
17,243 |
|
|
|
53,188 |
|
Operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
|
4,561 |
|
|
|
4,944 |
|
|
|
20,802 |
|
|
|
18,410 |
|
Sales and marketing |
|
|
9,476 |
|
|
|
12,971 |
|
|
|
46,091 |
|
|
|
60,140 |
|
General and administrative |
|
|
7,042 |
|
|
|
7,427 |
|
|
|
27,796 |
|
|
|
31,375 |
|
Impairment of goodwill |
|
|
- |
|
|
|
- |
|
|
|
14,701 |
|
|
|
- |
|
Impairment of long-lived and intangible assets |
|
|
1,501 |
|
|
|
323 |
|
|
|
7,676 |
|
|
|
323 |
|
Loss on disposal of property and equipment |
|
|
247 |
|
|
|
105 |
|
|
|
568 |
|
|
|
105 |
|
Total operating expenses |
|
|
22,827 |
|
|
|
25,770 |
|
|
|
117,634 |
|
|
|
110,353 |
|
Loss from operations |
|
|
(17,704 |
) |
|
|
(17,981 |
) |
|
|
(100,391 |
) |
|
|
(57,165 |
) |
Other (expense) income |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest expense |
|
|
(3,771 |
) |
|
|
(635 |
) |
|
|
(11,643 |
) |
|
|
(2,595 |
) |
Interest income |
|
|
26 |
|
|
|
17 |
|
|
|
139 |
|
|
|
91 |
|
Foreign currency loss |
|
|
(51 |
) |
|
|
(37 |
) |
|
|
(239 |
) |
|
|
(225 |
) |
Loss on extinguishment of debt |
|
|
- |
|
|
|
- |
|
|
|
(1,114 |
) |
|
|
- |
|
Other |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
18 |
|
Net loss before income taxes |
|
$ |
(21,500 |
) |
|
$ |
(18,636 |
) |
|
$ |
(113,248 |
) |
|
$ |
(59,876 |
) |
(Benefit) provision for income taxes |
|
|
(63 |
) |
|
|
(76 |
) |
|
|
11 |
|
|
|
(76 |
) |
Net loss |
|
$ |
(21,437 |
) |
|
$ |
(18,560 |
) |
|
$ |
(113,259 |
) |
|
$ |
(59,800 |
) |
Other comprehensive loss: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Foreign currency translation adjustments |
|
|
229 |
|
|
|
7 |
|
|
|
(183 |
) |
|
|
(15 |
) |
Total other comprehensive loss |
|
|
229 |
|
|
|
7 |
|
|
|
(183 |
) |
|
|
(15 |
) |
Total comprehensive loss |
|
$ |
(21,208 |
) |
|
$ |
(18,553 |
) |
|
$ |
(113,442 |
) |
|
$ |
(59,815 |
) |
Net loss per share basic and diluted |
|
$ |
(0.78 |
) |
|
$ |
(0.71 |
) |
|
$ |
(4.24 |
) |
|
$ |
(2.31 |
) |
Weighted-average number of shares used in calculating net loss per share, basic and diluted |
|
|
27,328,746 |
|
|
|
26,073,243 |
|
|
|
26,732,940 |
|
|
|
25,936,970 |
|
|
||||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS |
||||||||
(In thousands) |
||||||||
|
|
Year Ended |
|
|||||
|
|
2022 |
|
|
2021 |
|
||
Cash flows from operating activities |
|
|
|
|
|
|
||
Net loss |
|
$ |
(113,259 |
) |
|
$ |
(59,800 |
) |
Adjustments to reconcile net loss to net cash used in operating activities |
|
|
|
|
|
|
||
Stock-based compensation expense |
|
|
10,385 |
|
|
|
9,766 |
|
Depreciation and amortization |
|
|
5,180 |
|
|
|
5,648 |
|
Provision for bad debts |
|
|
224 |
|
|
|
(161 |
) |
Provision for inventory valuation |
|
|
3,083 |
|
|
|
70 |
|
Non-cash lease expense |
|
|
2,127 |
|
|
|
1,764 |
|
Change in fair value of contingent consideration |
|
|
(3,351 |
) |
|
|
(1,813 |
) |
Impairment of goodwill |
|
|
14,701 |
|
|
|
- |
|
Impairment of long-lived and intangible assets |
|
|
7,676 |
|
|
|
323 |
|
Loss on disposal of property and equipment |
|
|
568 |
|
|
|
105 |
|
Placed unit reserve |
|
|
646 |
|
|
|
155 |
|
Amortization of discount on debt |
|
|
686 |
|
|
|
128 |
|
Loss from deconsolidation |
|
|
35 |
|
|
|
- |
|
Deferred income taxes |
|
|
11 |
|
|
|
(76 |
) |
Loss on extinguishment of debt |
|
|
1,114 |
|
|
|
- |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
||
Accounts receivable |
|
|
1,162 |
|
|
|
12,400 |
|
Inventories |
|
|
449 |
|
|
|
(16,759 |
) |
Prepaid expenses and other assets |
|
|
(1,771 |
) |
|
|
1,458 |
|
Accounts payable |
|
|
(3,347 |
) |
|
|
798 |
|
Contract liabilities |
|
|
(844 |
) |
|
|
(892 |
) |
Accrued expenses and other liabilities |
|
|
(3,285 |
) |
|
|
(6,724 |
) |
Operating lease liabilities, current and long-term |
|
|
(2,347 |
) |
|
|
(1,761 |
) |
Net cash used in operating activities |
|
|
(80,157 |
) |
|
|
(55,371 |
) |
Cash flows from investing activities |
|
|
|
|
|
|
||
Purchases of property and equipment |
|
|
(11,610 |
) |
|
|
(5,895 |
) |
Acquisition of business, net of cash acquired |
|
|
- |
|
|
|
(1,304 |
) |
Net cash used in investing activities |
|
|
(11,610 |
) |
|
|
(7,199 |
) |
Cash flows from financing activities |
|
|
|
|
|
|
||
Proceeds from loans, net of discount |
|
|
99,094 |
|
|
|
- |
|
Proceeds from revolving loan facility |
|
|
- |
|
|
|
4,882 |
|
Repayment of loans |
|
|
(40,000 |
) |
|
|
- |
|
Payments of debt extinguishment costs |
|
|
(817 |
) |
|
|
- |
|
Payment of debt issuance costs |
|
|
(1,567 |
) |
|
|
- |
|
Repayments on revolving loan facility |
|
|
(6,608 |
) |
|
|
(3,162 |
) |
Payment of contingent consideration |
|
|
(135 |
) |
|
|
- |
|
Proceeds from issuance of common stock in connection with at-the-market offerings, net |
|
|
1,064 |
|
|
|
- |
|
Proceeds from issuance of common stock under Employee Stock Purchase Plan |
|
|
228 |
|
|
|
1,139 |
|
Proceeds from exercise of stock options |
|
|
65 |
|
|
|
1,511 |
|
Net cash provided by financing activities |
|
|
51,324 |
|
|
|
4,370 |
|
Effect of exchange rate changes on cash, cash equivalents and restricted cash |
|
|
(34 |
) |
|
|
(12 |
) |
Net decrease in cash, cash equivalents and restricted cash |
|
|
(40,477 |
) |
|
|
(58,212 |
) |
Cash, cash equivalents and restricted cash |
|
|
|
|
|
|
||
Beginning of period |
|
|
57,324 |
|
|
|
115,536 |
|
End of period |
|
$ |
16,847 |
|
|
$ |
57,324 |
|
Supplemental disclosures of cash flow information |
|
|
|
|
|
|
||
Interest paid during the period |
|
$ |
8,834 |
|
|
$ |
2,466 |
|
Property and equipment purchases in accounts payable and accrued expenses |
|
$ |
702 |
|
|
$ |
422 |
|
Issuance of common stock to satisfy contingent consideration |
|
$ |
5,630 |
|
|
$ |
- |
|
Issuance of common stock warrants in conjunction with long term debt |
|
$ |
1,201 |
|
|
$ |
- |
|
Issuance of common stock for services |
|
$ |
360 |
|
|
$ |
413 |
|
Issuance of common stock upon vesting of restricted stock units |
|
$ |
12 |
|
|
$ |
161 |
|
Non-GAAP Financial Measures
The following tables contain a reconciliation of net loss to Adjusted EBITDA for the three months and years ended |
||||||||||||||||
(unaudited) |
||||||||||||||||
|
|
Three Months Ended
|
|
|
Year Ended
|
|
||||||||||
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
||||
|
|
(in thousands) |
|
|||||||||||||
Net loss |
|
$ |
(21,437 |
) |
|
$ |
(18,560 |
) |
|
$ |
(113,259 |
) |
|
$ |
(59,800 |
) |
Interest expense, net |
|
|
3,745 |
|
|
|
618 |
|
|
|
11,504 |
|
|
|
2,504 |
|
(Benefit) provision for income taxes |
|
|
(63 |
) |
|
|
(76 |
) |
|
|
11 |
|
|
|
(76 |
) |
Depreciation and amortization |
|
|
1,174 |
|
|
|
1,467 |
|
|
|
5,180 |
|
|
|
5,648 |
|
EBITDA |
|
$ |
(16,581 |
) |
|
$ |
(16,551 |
) |
|
$ |
(96,564 |
) |
|
$ |
(51,724 |
) |
Foreign currency |
|
|
51 |
|
|
|
37 |
|
|
|
239 |
|
|
|
225 |
|
Loss on extinguishment of debt |
|
|
- |
|
|
|
- |
|
|
|
1,114 |
|
|
|
- |
|
Change in fair value of contingent consideration |
|
|
- |
|
|
|
(1,356 |
) |
|
|
(3,351 |
) |
|
|
(1,813 |
) |
Stock-based compensation |
|
|
2,760 |
|
|
|
2,569 |
|
|
|
10,385 |
|
|
|
9,766 |
|
Impairment of goodwill |
|
|
- |
|
|
|
- |
|
|
|
14,701 |
|
|
|
- |
|
Impairment of long-lived and intangible assets |
|
|
1,501 |
|
|
|
323 |
|
|
|
7,676 |
|
|
|
323 |
|
Loss on disposal of property and equipment |
|
|
247 |
|
|
|
105 |
|
|
|
568 |
|
|
|
105 |
|
Adjusted EBITDA |
|
$ |
(12,022 |
) |
|
$ |
(14,873 |
) |
|
$ |
(65,232 |
) |
|
$ |
(43,118 |
) |
The following tables contain a reconciliation of operating expenses to non-GAAP operating expenses and non-GAAP cash operating expenses for the three months and years ended |
||||||||||||||||
(unaudited) |
||||||||||||||||
|
|
Three Months Ended
|
|
|
Years Ended
|
|
||||||||||
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
||||
|
|
(in thousands) |
|
|||||||||||||
GAAP operating expenses |
|
$ |
22,827 |
|
|
$ |
25,770 |
|
|
$ |
117,634 |
|
|
$ |
110,353 |
|
Impairment of goodwill |
|
|
- |
|
|
|
- |
|
|
|
(14,701 |
) |
|
|
- |
|
Impairment of long-lived and intangible assets |
|
|
(1,501 |
) |
|
|
(323 |
) |
|
|
(7,676 |
) |
|
|
(323 |
) |
Loss on disposal of property and equipment |
|
|
(247 |
) |
|
|
(105 |
) |
|
|
(568 |
) |
|
|
(105 |
) |
Non-GAAP operating expenses |
|
|
21,079 |
|
|
|
25,342 |
|
|
|
94,689 |
|
|
|
109,925 |
|
Stock-based compensation |
|
|
(2,663 |
) |
|
|
(2,377 |
) |
|
|
(9,668 |
) |
|
|
(9,037 |
) |
Depreciation and amortization |
|
|
(342 |
) |
|
|
(484 |
) |
|
|
(1,709 |
) |
|
|
(1,915 |
) |
Termination benefits |
|
|
(30 |
) |
|
|
- |
|
|
|
(3,060 |
) |
|
|
- |
|
Loss from deconsolidation |
|
|
(35 |
) |
|
|
- |
|
|
|
(35 |
) |
|
|
- |
|
Change in fair value of contingent consideration |
|
|
- |
|
|
|
1,356 |
|
|
|
3,351 |
|
|
|
1,813 |
|
Non-GAAP cash operating expenses |
|
$ |
18,009 |
|
|
$ |
23,837 |
|
|
$ |
83,568 |
|
|
$ |
100,786 |
|
Supplemental Operating Metrics
|
|
|
|
|
|
|
|
|
|||||||
|
2022 |
|
|
2021 |
|
|
Change |
|
|||||||
|
Amount |
|
|
Amount |
|
|
Amount |
|
|
% |
|
||||
HVT 2.0 and precision flow units installed base |
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
24,327 |
|
|
|
23,368 |
|
|
|
959 |
|
|
|
4.1 |
% |
International |
|
12,439 |
|
|
|
11,848 |
|
|
|
591 |
|
|
|
5.0 |
% |
Total |
|
36,766 |
|
|
|
35,216 |
|
|
|
1,550 |
|
|
|
4.4 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Three Months Ended |
|
|
|
|
|
|
|
|||||||
|
2022 |
|
|
2021 |
|
|
Change |
|
|||||||
|
Amount |
|
|
Amount |
|
|
Amount |
|
|
% |
|
||||
HVT 2.0 and precision flow units sold and leased |
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
239 |
|
|
|
419 |
|
|
|
(180 |
) |
|
|
(43.0 |
)% |
International |
|
75 |
|
|
|
194 |
|
|
|
(119 |
) |
|
|
(61.3 |
)% |
Total |
|
314 |
|
|
|
613 |
|
|
|
(299 |
) |
|
|
(48.8 |
)% |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Disposable patient circuits sold |
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
104,302 |
|
|
|
108,200 |
|
|
|
(3,898 |
) |
|
|
(3.6 |
)% |
International |
|
24,551 |
|
|
|
34,395 |
|
|
|
(9,844 |
) |
|
|
(28.6 |
)% |
Total |
|
128,853 |
|
|
|
142,595 |
|
|
|
(13,742 |
) |
|
|
(9.6 |
)% |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Year Ended |
|
|
|
|
|
|
|
|||||||
|
2022 |
|
|
2021 |
|
|
Change |
|
|||||||
|
Amount |
|
|
Amount |
|
|
Amount |
|
|
% |
|
||||
HVT 2.0 and precision flow units sold and leased |
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
813 |
|
|
|
3,600 |
|
|
|
(2,787 |
) |
|
|
(77.4 |
)% |
International |
|
531 |
|
|
|
2,972 |
|
|
|
(2,441 |
) |
|
|
(82.1 |
)% |
Total |
|
1,344 |
|
|
|
6,572 |
|
|
|
(5,228 |
) |
|
|
(79.5 |
)% |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Disposable patient circuits sold |
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
331,044 |
|
|
|
452,605 |
|
|
|
(121,561 |
) |
|
|
(26.9 |
)% |
International |
|
118,226 |
|
|
|
200,901 |
|
|
|
(82,675 |
) |
|
|
(41.2 |
)% |
Total |
|
449,270 |
|
|
|
653,506 |
|
|
|
(204,236 |
) |
|
|
(31.3 |
)% |
View source version on businesswire.com: https://www.businesswire.com/news/home/20230223005397/en/
Investor Relations:
Source:
FAQ
What were Vapotherm's Q4 2022 financial results?
How did Vapotherm's revenue perform in fiscal year 2022?
What is Vapotherm's outlook for 2023?
What were the significant changes in Vapotherm's operating expenses?